Ziccardi R J, Cooper N R
J Exp Med. 1978 Feb 1;147(2):385-95. doi: 10.1084/jem.147.2.385.
Activation of the first component of human complement (C1) in human sera can be readily detected in double immunodiffusion studies with anti-C1q, anti- C1r, and anti-C1s as it produces a characteristic pattern quite different from that of precursor C1. Native macromolecular C1 gives a continuous line of precipitation with antisera to C1q, C1r, and C1s in double diffusion studies. After activation of C1 by incubation of serum with complement activators, three major changes occurred in the Ouchterlony pattern. First, spurring of the C1s precipitin line over that of macromolecular C1, indicating release of C1s from C1, was observed with low doses of activator. Release of C1s was quantitated by single radial diffusion and shown to be complete with the highest activator dose examined. Second, C1q was released with larger activator doses as shown also by spurring of the precipitin line due to this component over the remaining macromolecular C1. Third, and most surprising, C1r antigenicity was progressively lost as the activator dose was increased and no C1r line remained with the highest dose of activator tested. This was not true with C1s as there was no change in the total C1s concentration in serum incubated with various activator doses. These observations provide two approaches to the quantitation of C1 activation in human serum. First, C1r and C1s can be quantitated by single radial diffusion. A decrease in the C1r:C1s ratio correlates with activation. Second, C1s released by the activation can be quantitated by single radial diffusion if the agarose contains high concentrations of anti-C1q to confine C1, also containing C1s, to the area near the application well, and lesser concentrations of anti-C1s to permit free C1s to produce a measurable ring. The extent of release of C1s also correlates with activation. These immunochemical techniques to quantitate C1 activation directly inserum do not require specialized reagents. It is hoped that they will be useful in screening pathological sera and in monitoring the status of the complement system in patients.
在使用抗C1q、抗C1r和抗C1s进行的双向免疫扩散研究中,人血清中人类补体第一成分(C1)的激活很容易被检测到,因为它产生的特征性沉淀模式与前体C1的模式有很大不同。在双向扩散研究中,天然大分子C1与抗C1q、抗C1r和抗C1s抗血清产生连续的沉淀线。在用补体激活剂孵育血清激活C1后,在欧氏免疫扩散图谱中出现了三个主要变化。首先,在用低剂量激活剂时,观察到C1s沉淀线在大分子C1沉淀线之上出现刺突,这表明C1s从C1中释放出来。通过单向辐射扩散对C1s的释放进行定量,结果显示在所检测的最高激活剂剂量下释放完全。其次,使用较大剂量激活剂时,C1q也会释放出来,这也表现为该成分的沉淀线在剩余的大分子C1之上出现刺突。第三,也是最令人惊讶的是,随着激活剂剂量的增加,C1r的抗原性逐渐丧失,在测试的最高剂量激活剂下,没有C1r沉淀线残留。C1s的情况并非如此,在用不同剂量激活剂孵育的血清中,总C1s浓度没有变化。这些观察结果提供了两种定量人血清中C1激活的方法。第一,C1r和C1s可以通过单向辐射扩散进行定量。C1r:C1s比值的降低与激活相关。第二,如果琼脂糖中含有高浓度的抗C1q,将含有C1s的C1限制在加样孔附近区域,同时含有较低浓度的抗C1s,使游离的C1s产生可测量的沉淀环,那么通过单向辐射扩散可以对激活过程中释放的C1s进行定量。C1s的释放程度也与激活相关。这些直接在血清中定量C1激活的免疫化学技术不需要特殊试剂。希望它们在筛选病理性血清和监测患者补体系统状态方面有用。